Drugs News and Research

RSS

Drug formulation services for highly potent active pharmaceutical ingredients provided by Evonik

Evonik Industries has broadened its capabilities in finished drug product formulation and clinical supply manufacturing and can now handle drug products containing highly potent active pharmaceutical ingredients (HPAPIs) in Darmstadt, Germany, and Birmingham, Alabama/USA. Investments in high containment facilities and upgrades in the laboratory and GMP areas in Birmingham enable Evonik to handle HPAPIs with occupational exposure limits (OEL) as low as 0.1μg/m3 and in Darmstadt as low as 1 μg/m3. Starting 2014, OEL as low as 0.1μg/m3 will also be possible in Darmstadt.

8 Nov 2013

Peptide from cow's milk exhibits potent anticancer capability against human stomach cancer cell cultures

New research from a team of researchers in Taiwan indicates that a peptide fragment derived from cow's milk, known as lactoferricin B25 (LFcinB25), exhibited potent anticancer capability against human stomach cancer cell cultures.

8 Nov 2013

Northwestern Medicine receives $12 million to continue organ transplant research with stem cells

An innovative Northwestern Medicine- research program investigating if stem cells may be the key to allowing organ transplant patients to stop taking immunosuppressive drugs has received $12 million in research funding. The grant will allow researchers to finish Phase II of the clinical trials and begin Phase III.

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today.

8 Nov 2013

Amneal to launch AB-rated generic for Loestrin 24 Fe

Amneal Pharmaceuticals LLC will launch its AB-rated generic for Loestrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) 1 mg/20 mcg, 75 mg the first week of January 2014.

8 Nov 2013

Four-year study to develop targeted approach to psoriasis treatment

A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.

8 Nov 2013

Cancer pioneer James Allison wins 2013 Innovations Award for bioscience

For basic science research that opened a completely new approach for treating cancer, The Economist has named James Allison, Ph.D., professor and chair of Immunology at The University of Texas MD Anderson Cancer Center, as its 2013 Innovations Award winner in Bioscience.

8 Nov 2013

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

Findings raise prospects for new therapies to protect heart from progressive disease

Some of the most commonly prescribed drugs for the treatment of heart failure are beta-blockers and nitrates, which help to relax blood vessels and decrease the heart's workload. The drugs were thought to produce those effects through distinct molecular pathways, but according to a new study led by scientists at Temple University School of Medicine, both types of drugs may help the failing heart by counteracting the effects of an enzyme known as GRK2.

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

Researchers identify chain reaction that triggers regrowth of some damaged nerve cell

Researchers at Washington University School of Medicine in St. Louis have identified a chain reaction that triggers the regrowth of some damaged nerve cell branches, a discovery that one day may help improve treatments for nerve injuries that can cause loss of sensation or paralysis.

8 Nov 2013

Researchers able to regrow bone, hair, soft tissues and cartilage in mouse model

Young animals are known to repair their tissues effortlessly, but can this capacity be recaptured in adults? A new study from researchers at the Stem Cell Program at Boston Children's Hospital suggests that it can. By reactivating a dormant gene called Lin28a, which is active in embryonic stem cells, researchers were able to regrow hair and repair cartilage, bone, skin and other soft tissues in a mouse model.

8 Nov 2013

$Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D$

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs.

8 Nov 2013

Nanoparticles with chemotherapeutic drugs can kill drug-resistant breast cancer cells

Nanoparticles filled with chemotherapeutic drugs can kill drug-resistant breast cancer cells, according to a study published in the scientific journal Biomaterials.

8 Nov 2013

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team, led by Dr. Lewis Cantley and investigators at Weill Cornell Medical College, has identified a family of enzymes they say is crucial for the growth of cancers that have genetic aberrations in p53.

8 Nov 2013

Lactoferricin B25 derived from cow's milk shows promise for treatment of gastric cancer

8 Nov 2013

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

Vitamin D and calcium improves bone density in male veterans treated with AEDs

8 Nov 2013

UC researchers receive FDA grant to study generic tacrolimus in high-risk transplant patients

Transplant researchers at the University of Cincinnati have received a grant from the U.S. Food and Drug Administration to study the safety and efficacy of a generic immunosuppressive drug in high-risk transplant patients.

7 Nov 2013

Drugs News and Research

Drug formulation services for highly potent active pharmaceutical ingredients provided by Evonik

Peptide from cow's milk exhibits potent anticancer capability against human stomach cancer cell cultures

Northwestern Medicine receives $12 million to continue organ transplant research with stem cells

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Amneal to launch AB-rated generic for Loestrin 24 Fe

Four-year study to develop targeted approach to psoriasis treatment

Cancer pioneer James Allison wins 2013 Innovations Award for bioscience

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

Findings raise prospects for new therapies to protect heart from progressive disease

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Researchers identify chain reaction that triggers regrowth of some damaged nerve cell

Researchers able to regrow bone, hair, soft tissues and cartilage in mouse model

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

Nanoparticles with chemotherapeutic drugs can kill drug-resistant breast cancer cells

Researchers identify enzymes that are crucial for growth of cancers with genetic aberrations in p53

Lactoferricin B25 derived from cow's milk shows promise for treatment of gastric cancer

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

Vitamin D and calcium improves bone density in male veterans treated with AEDs

UC researchers receive FDA grant to study generic tacrolimus in high-risk transplant patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News